Launch
FDA OKs Drug Linked to Longer Survival in Fatal Genetic Disorder
The Brief
- The FDA approved adrabetadex (Lembaz) injection on Tuesday for patients with infantile-onset Niemann-Pick disease type C (NPC).
- NPC is described as a rare and fatal genetic disorder.
- The approval is indicated for adults and children weighing at least 15 lb; the source snippet is truncated before the full indication.
Why it matters
This is the first approval of a treatment for infantile-onset NPC, a rare fatal disorder, and the reported link to longer survival could matter for clinicians and families managing the disease.
Who’s affected
- clinicians treating rare genetic disorders
- patients and families affected by Niemann-Pick disease type C
- #fda approval
- #niemann-pick
- #rare disease
- #genetic disorders
- #drugs
(MedPage Today) -- The FDA approved adrabetadex (Lembaz) injection on Tuesday for patients with infantile-onset Niemann-Pick disease type C (NPC), a rare and fatal genetic disorder. Indicated for adults and children weighing at least 15 lb whose...